Lack of ErbB-2 Oncogene Product Overexpression in Soft Tissue Sarcomas

Merimsky, Ofer; Issakov, Josephine; Schwartz, Ignat; Dadia, Solomon; Kollender, Yehuda; Bickels, Jacob; Inbar, Moshe; Meller, Isaac

doi:10.1080/028418602760169424

Cited by 7 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nuciforo et al41 have also shown one case of synovial sarcoma from the neck to be C‐ er b‐B2 (HER2/ neu ) positive. Consistent with these previous reports, we observed the epithelioid cells to stain more intensely than the spindle cells 29, 39–42. However, in contradiction to these same studies, we also observed strong positivity in the spindle cell component of the monophasic (patient 2) and biphasic (patients 1 and 3) head and neck cases.…”

Section: Discussionsupporting

confidence: 82%

“…Further studies will be needed to determine whether a large percentage of head and neck synovial sarcomas are strongly positive for C‐ er b‐B2 (HER2/ neu ) expression or whether this was an isolated observation. George et al39 first reported six cases of non–head and neck synovial sarcoma that were immunohistochemically negative for C‐ er b‐B2 (HER2/ neu ) expression, and Merimsky et al40 published an additional 25 cases that were also negative. Recently, Allander et al29 reported that the epithelial component of five of five biphasic synovial sarcomas and three of 32 monophasic synovial sarcomas were immunohistochemically positive.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck

et al. 2005

View full text Add to dashboard Cite

These results demonstrate that C-erb-B2 (HER2/neu) may play a role in the tumorigenesis of synovial sarcoma; and, therefore, antigrowth factor therapies may provide a previously unrecognized pharmaceutical approach to soft tissue tumors. The data also suggest that although synovial sarcoma of the head and neck and synovial sarcoma of the extremities have similar morphologic features, they may be clinically and mechanistically distinct entities.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Reports demonstrated that ERBB2 is overexpressed in 30 -50% of STSs. 29,31,33,34 However, Merimsky et al 35 found no overexpression of ERBB2 in 230 cases of STS. There have been several reports of KIT immunostaining in a limited number of STSs, other than GISTs, including clear cell sarcoma, synovial sarcoma, dermatofibrosarcoma protuberans, and Ewing sarcoma.…”

Section: Discussionmentioning

confidence: 99%

Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas

Sato

Wada

Kawai³

et al. 2005

Cancer

View full text Add to dashboard Cite

BACKGROUNDLittle is known about the expression of receptor tyrosine kinases in adult soft tissue sarcomas (STS). In the current study, the authors analyzed the expression of epidermal growth factor receptor (EGFR), ERBB2, and KIT in 281 patients with STS who were treated in a single institution. Verification of the presence of an association with prognosis was performed.METHODSThe current study included 281 adult patients with STS of the extremity and trunk who were diagnosed and treated in the National Cancer Center, Tokyo. Expression was assessed using immunohistochemical stains for EGFR, ERBB2, and KIT on formalin‐fixed, paraffin‐embedded tissue sections by standard avidin‐biotin peroxidase complex technique and EGFR detection system.RESULTSPositive staining of EGFR was observed in 168 of 281 (60%) patients. Positive staining was common in pleomorphic malignant fibrous histiocytomas (89%), myxofibrosarcomas (89%), synovial sarcomas (76%), malignant peripheral nerve sheath tumors (89%), and leiomyosarcomas (73%). It was less common in well differentiated liposarcomas (38%), fibrosarcomas (36%), and myxoid liposarcomas (6%). In contrast, positive staining of ERBB2 and KIT was very limited. Increased levels of EGFR were significantly associated with a decreased probability of overall survival (P = 0.01), although by univariate analysis; probability of overall survival at 5 years was 64% in patients with increased levels of EGFR and 79% in patients without such overexpression. The overexpression of EGFR was significantly associated with histologic grade (P < 0.001). Moreover, stratified log‐rank test revealed that there is an interrelation between EGFR overexpression and histologic grade.CONCLUSIONSEGFR overexpression was found to be a negative prognostic factor of adult STS, which is strongly associated with histologic grade. STS patients with EGFR overexpression may benefit from treatment with currently available biospecific inhibitors for EGFR. Cancer 2005. © 2005 American Cancer Society.

show abstract

“…With the exception of osteosarcoma [272][273][274][275][276][277][278][279][280][281][282][283][284][285][286][287], synovial sarcoma [287][288][289][290][291], rhabdomyosarcoma [292][293][294], carcinosarcoma, and mixed Müllerian tumors, the latter two originating in the gynecologic tract that will be discussed below, there is no consistent evidence of HER2/neu expression or overexpression in the common soft tissue sarcomas [295][296][297][298][299][300][301][302][303][304]. HER2/neu is overexpressed in >40% of osteosarcomas [275,305], but is not a valid target in Ewings sarcoma [299,304,306] (consistent with the data above pertaining to lack of HER2/neu expression or overexpression in peripheral neuroendocrine tissues and tumors), chondrosarcomas or desmoid tumors [307].…”

Section: Sarcomasmentioning

confidence: 99%

HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology

Nelson¹

2014

Clinical Investigation

View full text Add to dashboard Cite

No biological molecule in the field of oncology has been more extensively or more successfully targeted for therapeutic intent than the product of the c-erbB2 gene, HER2/neu. This is the second of a comprehensive three-part review of the foundation for and therapeutic targeting of HER2/neu. The distribution of HER2/neu overexpression and/or gene amplification by individual tumor sites and histologies will be comprehensively surveyed and described. This provides a bridge between the primarily basic science focused Part I, and the survey of clinical applications to follow in Part III. In combination, this comprehensive survey will identify opportunities and promising areas for future evaluation of HER2/neu-targeted therapies, highlighting the importance of HER2/neu as an increasingly important therapeutic target.

show abstract

Lack of ErbB-2 Oncogene Product Overexpression in Soft Tissue Sarcomas

Cited by 7 publications

References 16 publications

C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck

C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck

Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas

HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology

Contact Info

Product

Resources

About